Real World Safety and Outcome of First Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (“PEMBROREAL” Study) DOI Open Access
Alessandro Cafaro, Flavia Foca, Oriana Nanni

et al.

Published: April 16, 2024

Results from the phase III Keynote-024 clinical trial have established Pembrolizumab monotherapy as first-line standard of care for patients with metastatic NSCLC who PD-L1 expression ≥ 50%, EGFR and ALK wild-type. However, given differences between treated in routine practice within a trial, real-world data are needed to confirm treatment benefit practice. Given lack on large cohorts long follow-up, we designed retrospective observational study were Pembrolizumab, starting its reimbursement eligibility until December 2020. The primary endpoints assess PFS OS using Kaplan-Meier method, response safety. We followed 880 (median follow-up: 35.1 months) February 2022. Median 8.6 months (95% CI: 7.6-10.0) 25.5 21.8-31.6), respectively. also found that ECOG PS, smoking habit prognostic factors PFS, while age, sex, histology had an impact OS. Multivariable analysis confirms role both 39.9% reported adverse event, but only 6.3% discontinued therapy due toxicity. Our results suggest long-term setting well safety profile consistent Keynote-042. Many collected variables appear influence outcome, these exploratory unadjusted analyses should be interpreted caution.

Language: Английский

The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions DOI Open Access
Angela Rina, Debora Maffeo, Francesca Minnai

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(16), P. 2882 - 2882

Published: Aug. 19, 2024

Lung cancer, including both non-small cell lung cancer and small remains the leading cause of cancer-related mortality worldwide, representing 18% total deaths in 2020. Many patients are identified already at an advanced stage with metastatic disease have a worsening prognosis. Recent advances genetic understanding opened new avenues for personalized treatments targeted therapies. This review examines latest discoveries genetics discusses key biomarkers, analyzes current clinical therapies based on this information. It will conclude discussion future prospects potential research directions.

Language: Английский

Citations

5
Real World Safety and Outcome of First Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (“PEMBROREAL” Study) DOI Open Access
Alessandro Cafaro, Flavia Foca, Oriana Nanni

et al.

Published: April 16, 2024

Results from the phase III Keynote-024 clinical trial have established Pembrolizumab monotherapy as first-line standard of care for patients with metastatic NSCLC who PD-L1 expression ≥ 50%, EGFR and ALK wild-type. However, given differences between treated in routine practice within a trial, real-world data are needed to confirm treatment benefit practice. Given lack on large cohorts long follow-up, we designed retrospective observational study were Pembrolizumab, starting its reimbursement eligibility until December 2020. The primary endpoints assess PFS OS using Kaplan-Meier method, response safety. We followed 880 (median follow-up: 35.1 months) February 2022. Median 8.6 months (95% CI: 7.6-10.0) 25.5 21.8-31.6), respectively. also found that ECOG PS, smoking habit prognostic factors PFS, while age, sex, histology had an impact OS. Multivariable analysis confirms role both 39.9% reported adverse event, but only 6.3% discontinued therapy due toxicity. Our results suggest long-term setting well safety profile consistent Keynote-042. Many collected variables appear influence outcome, these exploratory unadjusted analyses should be interpreted caution.

Language: Английский

Citations

2